MAIA Biotechnology's stock price fell 29% due to a discounted stock issuance.

LootboxPhobia · 2026-03-03T17:26:18+00:00

MAIA Biotechnology's stock price dropped 29% to $1.47 in pre-market trading on Tuesday after the company announced a $30 million public offering at $1.50 per share, representing a 27.5% discount. The proceeds will be used for clinical trials and operational expenses.

LootboxPhobia

2026-03-03 17:26:18

Abstract generation in progress

Investing.com – MAIA Biotechnology stock fell 29% to $1.47 in pre-market trading on Tuesday after the biotech announced a $30 million public offering at a significant discount.

The company sold 20 million shares at $1.50 per share on Monday, a 27.5% discount to the previous trading day’s closing price.

According to MAIA Biotechnology, healthcare-focused investors alongside existing shareholders led the offering.

Proceeds will be used for clinical trials, working capital, and general corporate purposes.

Konik Capital Partners served as the sole bookrunner for the offering.

According to the prospectus, as of Monday, MAIA Biotechnology had 38.7 million shares outstanding.

This article was translated with the assistance of artificial intelligence. For more information, see our Terms of Use.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

1 Likes